Mechanism: Carvykti similarly targets BCMA, but with engineering adaptations designed to enhance the persistence and activity of T-cells against BCMA-expressing myeloma cells, thus providing another effective avenue for treatment in this patient population. Here, TNFRSF17 is linked to plasma cell myeloma.